News coverage about Prana Biotechnology (NASDAQ:PRAN) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prana Biotechnology earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.1040672240783 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Prana Biotechnology (NASDAQ PRAN) opened at 2.76 on Friday. The stock’s market cap is $4.09 million. The stock’s 50 day moving average is $2.68 and its 200 day moving average is $2.51. Prana Biotechnology has a 52-week low of $1.52 and a 52-week high of $5.50.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/prana-biotechnology-pran-given-news-impact-score-of-0-08/1538060.html.

Prana Biotechnology Company Profile

Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders.

Insider Buying and Selling by Quarter for Prana Biotechnology (NASDAQ:PRAN)

Receive News & Ratings for Prana Biotechnology Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.